[go: up one dir, main page]

MX2017016024A - Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. - Google Patents

Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.

Info

Publication number
MX2017016024A
MX2017016024A MX2017016024A MX2017016024A MX2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A
Authority
MX
Mexico
Prior art keywords
skin disorders
methods
nicotinamide riboside
compositions
treatment
Prior art date
Application number
MX2017016024A
Other languages
English (en)
Other versions
MX389207B (es
Inventor
Antonio Alminana Daniel
Alexander Marcotulli Eric
Michael Bowen Paul
Pershing Guarente Leonard
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of MX2017016024A publication Critical patent/MX2017016024A/es
Publication of MX389207B publication Critical patent/MX389207B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones que contienen una combinación de nicotinamida ribósido y pteroestilbeno para tratar trastornos de la piel, y métodos para tratar trastornos de la piel empleando estas composiciones y sus equivalentes. Los trastornos de la piel que se tratan empleando estas composiciones o métodos incluyen trastornos de la piel relacionados con la exposición al sol, trastornos inflamatorios de la piel, trastornos de la piel relacionados con enfermedades autoinmunológicas y trastornos de la piel relacionados con el cáncer. En una realización, las composiciones que contienen una combinación de nicotinamida ribósido y pteroestilbeno se preparan como formulaciones orales.
MX2017016024A 2015-06-10 2016-02-25 Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. MX389207B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173733P 2015-06-10 2015-06-10
PCT/US2016/019653 WO2016200447A1 (en) 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Publications (2)

Publication Number Publication Date
MX2017016024A true MX2017016024A (es) 2018-08-15
MX389207B MX389207B (es) 2025-03-20

Family

ID=57503873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016024A MX389207B (es) 2015-06-10 2016-02-25 Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.
MX2021012600A MX2021012600A (es) 2015-06-10 2017-12-08 Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012600A MX2021012600A (es) 2015-06-10 2017-12-08 Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel.

Country Status (13)

Country Link
US (2) US11426398B2 (es)
EP (1) EP3307754B1 (es)
JP (1) JP2018517774A (es)
KR (1) KR20180021784A (es)
CN (1) CN107849083A (es)
AU (2) AU2016274126A1 (es)
CA (1) CA2989115C (es)
ES (1) ES2932801T3 (es)
MX (2) MX389207B (es)
RU (1) RU2017145692A (es)
TW (1) TWI725033B (es)
WO (1) WO2016200447A1 (es)
ZA (1) ZA201800056B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307754B1 (en) 2015-06-10 2022-09-14 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
ES2924710T3 (es) 2017-03-17 2022-10-10 Elysium Health Inc Ribósido de nicotinamida para uso en tratamiento o prevención de daño hepático
US20180303861A1 (en) * 2017-04-24 2018-10-25 Eric Marcotulli Treating and preventing kidney damage
JP7143402B2 (ja) * 2017-05-17 2022-09-28 ウニベルシタ デ バレンシア－エストゥディ ヘネラル ニコチンアミドリボシドを使用する運動ニューロン疾患の治療及び予防
CN111093676A (zh) * 2017-05-18 2020-05-01 益力舒健康公司 改善睡眠的方法和组合物
CN111542312A (zh) 2017-07-28 2020-08-14 老龄化控制中心股份公司 预防和逆转衰老方面的组合物和方法
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
CN111601814A (zh) * 2017-10-19 2020-08-28 益力舒健康公司 Tdp-43相关疾病的预防和治疗
US20200384004A1 (en) * 2017-12-01 2020-12-10 Elysium Health, Inc. Methods and compositions for treating glaucoma
WO2019108873A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
WO2020068705A1 (en) 2018-09-25 2020-04-02 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
WO2020176445A1 (en) * 2019-02-26 2020-09-03 Universitat De Valencia-Estudi General Methods and compositions for treating motor neuron diseases
WO2020190703A1 (en) * 2019-03-21 2020-09-24 Elysium Health, Inc. Methods for wound treatment
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
CN113712193A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 修复皮肤系统的组合物制备方法及其用途
WO2022026612A1 (en) * 2020-07-30 2022-02-03 Hernandez Vazquez Moises Nutritional supplements for repairing muscle and defending against deterioration from human aging
EP4380577A1 (en) * 2021-08-02 2024-06-12 Nuvamid SA Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK1957086T3 (en) * 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
CN103547256A (zh) 2011-03-23 2014-01-29 加利福尼亚大学校务委员会 炎性和传染性皮肤病的治疗
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CA2928656C (en) * 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
US10485814B2 (en) 2014-06-06 2019-11-26 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
JP7244163B2 (ja) * 2015-03-16 2023-03-22 クロマデックス，インコーポレイテッド ニコチン酸リボシドまたはニコチンアミドリボシド組成物、その還元誘導体、およびその使用
WO2016149277A1 (en) 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
EP3307754B1 (en) 2015-06-10 2022-09-14 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Also Published As

Publication number Publication date
EP3307754A4 (en) 2019-03-27
AU2020286208B2 (en) 2022-11-10
ZA201800056B (en) 2023-10-25
EP3307754B1 (en) 2022-09-14
TWI725033B (zh) 2021-04-21
ES2932801T3 (es) 2023-01-26
US12109206B2 (en) 2024-10-08
EP3307754A1 (en) 2018-04-18
CA2989115A1 (en) 2016-12-15
RU2017145692A (ru) 2019-07-10
RU2017145692A3 (es) 2019-07-31
TW201713322A (zh) 2017-04-16
KR20180021784A (ko) 2018-03-05
JP2018517774A (ja) 2018-07-05
CN107849083A (zh) 2018-03-27
WO2016200447A1 (en) 2016-12-15
MX389207B (es) 2025-03-20
AU2016274126A1 (en) 2018-01-18
CA2989115C (en) 2024-01-02
US20180353497A1 (en) 2018-12-13
US20220362233A1 (en) 2022-11-17
AU2020286208A1 (en) 2021-01-07
US11426398B2 (en) 2022-08-30
MX2021012600A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
MX2017016024A (es) Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX385845B (es) Usos y composiciones de la flagelina
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
MX372723B (es) Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
MX383484B (es) Método para tratar el cáncer.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
MX2015003701A (es) Composiciones para tratamiento.
MX2018015410A (es) Esteres de oxaborol y sus usos.
MX377300B (es) Terapia con células madre en patologías endometriales.
EA201690323A1 (ru) Способы лечения заболеваний уха у детей